Can-Fite BioPharma Annual Meeting Adjourned Due to Lack of Quorum

Ticker: CANF · Form: 6-K · Filed: Jun 23, 2025 · CIK: 1536196

Can-Fite Biopharma LTD. 6-K Filing Summary
FieldDetail
CompanyCan-Fite Biopharma LTD. (CANF)
Form Type6-K
Filed DateJun 23, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-meeting, adjournment

TL;DR

Can-Fite BioPharma's shareholder meeting postponed to June 30th due to no-shows. Big decisions on hold.

AI Summary

Can-Fite BioPharma Ltd. announced on June 23, 2025, that its Annual General Meeting of Shareholders was adjourned for one week due to a lack of quorum. The meeting will now be reconvened on Monday, June 30, 2025, at 3:00 p.m. Israel time at the company's offices in Ramat Gan, Israel.

Why It Matters

The adjournment of the annual meeting due to a lack of quorum may indicate shareholder disengagement or potential issues with corporate governance, which could impact future decision-making and investor confidence.

Risk Assessment

Risk Level: medium — Adjournment due to lack of quorum can signal potential shareholder apathy or governance concerns, which may lead to uncertainty and impact stock performance.

Key Numbers

Key Players & Entities

FAQ

Why was the Annual General Meeting adjourned?

The Annual General Meeting was adjourned due to a lack of quorum.

When will the Annual General Meeting be reconvened?

The Annual General Meeting will be reconvened on Monday, June 30, 2025.

What time is the reconvened meeting?

The reconvened meeting is scheduled for 3:00 p.m. Israel time.

Where will the reconvened meeting be held?

The reconvened meeting will be held at the Company's offices located at 26 Ben Gurion Street, Ramat Gan, Israel.

What is the company's exact name as specified in its charter?

The company's exact name is CAN-FITE BIOPHARMA LTD.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on June 23, 2025 regarding Can-Fite BioPharma Ltd. (CANF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing